Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eva Edwards

Nurse Practitioner, Family Manchester, KY Nurse Practitioner

NPI 1396964102 CMS profile 11167310

204 Town Branch Rd, Manchester, KY 40962

Open in the dashboard

General payments

$14,023

495 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eva Edwards of Manchester, KY is reported in the CMS Open Payments database as having received $14,023 across 495 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,399 82
2024 General $1,325 89
2023 General $4,109 79
2022 General $5,664 97
2021 General $1,525 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eva Edwards
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Eva Edwards were reported at $1,399. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Eva Edwards Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,525 $124 $35–$379 $132
2022 $5,664 $141 $44–$430 $149
2023 $4,109 $154 $49–$476 $160
2024 $1,325 $165 $51–$504 $164
2025 $1,399 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $8,535 101 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,490 157 payments
  3. ITI, Inc. $636 48 payments
  4. Indivior Inc. $394 17 payments
  5. Otsuka America Pharmaceutical, Inc. $384 20 payments
  6. Braeburn Inc. $352 17 payments
  7. Biodelivery Sciences International, Inc. $279 30 payments
  8. Amgen Inc. $266 14 payments
  9. Alkermes, Inc. $252 12 payments
  10. AstraZeneca Pharmaceuticals LP $181 9 payments
  11. Other $1,254 70 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,875 5 payments
  2. Food and Beverage $6,832 486 payments
  3. Travel and Lodging $316 4 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $7,734 45 payments
  2. RELISTOR Gastroenterology $735 78 payments
  3. CAPLYTA $475 37 payments
  4. XIFAXAN $402 49 payments
  5. SUBLOCADE $394 17 payments
  6. MAVYRET $392 17 payments
  7. TRULANCE $361 46 payments
  8. BRIXADI $352 17 payments
  9. RELISTOR Gastroenterology $340 31 payments
  10. UBRELVY $332 30 payments
  11. Other $4,231 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

732

Median for Nurse Practitioner: 389

Drug cost

$95,677

Median for Nurse Practitioner: $21,885

Branded share of claims

28.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 11 $25,901
Mounjaro Tirzepatide Brand 14 $14,549
Linzess Linaclotide Brand 25 $13,045
Ubrelvy Ubrogepant Brand 12 $11,620
Farxiga Dapagliflozin Propanediol Brand 13 $8,508
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 72 $7,666
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 16 $7,096
Vilazodone Hcl Generic 18 $1,569
Megestrol Acetate Generic 15 $966
Omega-3 Acid Ethyl Esters Generic 24 $631

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
$284 11 —
VRAYLAR
$175 — —
BRIXADI
$111 — —
MAVYRET
$107 — —
REXULTI
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

495 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record